David Rafei-Shamsabadi

7PUBLICATIONS
13CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiologyNanotechnology not elsewhere classifiedTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 26, 2024
Epidermolysis-Bullosa-Associated Squamous Cell Carcinomas Support an Immunosuppressive Tumor Microenvironment: Prospects for Immunotherapy.

David Rafei-Shamsabadi, Lena Scholten, Sisi Lu

|Feb 15, 2022
Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy.

David Rafei-Shamsabadi, Saskia Lehr, Max Behrens

|Nov 22, 2021
Esophageal carcinoma in severe recessive dystrophic epidermolysis bullosa-an underestimated complication?

A Schwieger-Briel, L Trefzer, H Schumann

|Oct 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.

Ulrike Leiter, Carmen Loquai, Lydia Reinhardt

|Jul 30, 2020
GNAQ/11 mutant nonuveal melanoma: same same but different.

D Rafei-Shamsabadi

|Mar 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.

Teresa Amaral, Felix Kiecker, Sarah Schaefer

Pageof 2

Frequent Collaborators

3 joint publications

Frank Meiss

1 joint publications

A Schwieger-Briel

1 joint publications

H Schumann

1 joint publications

A Reimer-Taschenbrecker